Proteotech Inc.

University of Washington

Other

Cognitive Clarity Inc.

Protamed, Inc.

Alan D Snow

Gerardo M Castillo

Thomas P Lake

Beth P Nguyen

Joel Cummings

Qubai Hu

Virginia J Sanders

Judy Cam

Lesley Larsen

Luke A Esposito

F Michael Hudson

Stephen D Lorimer

David Samuel Larsen

Rex T Weavers

Manfred Weigele

David Llewellyn Coffen

Marisa C Yadon

Charlotte Coffen, Legal Representative

Paula Y Choi

Grace A Maresh

John R Hassell

Ken-Ichiro Fukuchi

Anil M Kumar

Franz F Hefti

Seok-Rye Choi

Ximin Li

Kelsey Hanson

Esposito A Luke

Elizabeth Nguyen

Deborah A DeSantis

Geoffrey Golding

Joel A Cummings

Anil Kumar

David S Larsen

Beth Nguyen

Composition and methods for treating brain 'plaques' and/or 'tangles' in a subject wherein the method comprises administration of a therapeutically effective amount of a composition comprising a black currant extract,extract, and an oolong tea extract.

Compositions and methods for the treatment of 'plaques and tangles' in humans and animals

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncariaextract and an oolong tea extract.

Compositions and methods for the treatment of plaques and tangles in humans and animals

Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising anextract and an oolong tea extract. Compositions containing anextract in combination with an oolong tea extract.

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprisingextract and an oolong tea extract.

This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.

Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies

Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Isolation, purification and synthesis of procyanidin B2 and uses thereof

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

The use of 3,4,3',4&#x2032;-tetrahydroxychalcone in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's

The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.

Proteoglycan splice variants as therapeutics and diagnostics for amyloid diseases

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions, and methods for the treatment of &#x3b2;-amyloid diseases and synucleinopathies

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Growing community of inventors

Lynnwood, WA, United States of America

Alan D Snow